Vitamins that may be helpful
A variety of vitamins, minerals, amino acids, and other supplements may help with symptoms
and deficiencies associated with diabetes.
Multiple
Vitamin–Mineral Supplement
In a double-blind study, supplementation of middle-aged and elderly diabetics with a multiple
vitamin and mineral preparation for one year reduced the risk of infection by more than 80%,
compared with a placebo.78
Chromium
Medical reports dating back to 1853, as well as modern research, indicate that chromium-rich
brewer’s yeast (9 grams per day) can be
useful in treating type 2 diabetes.79 80 In recent years, chromium has
been shown to improve glucose levels and related variables in people with glucose intolerance
and type 2, gestational, and steroid-induced diabetes.81 82 Improved
glucose tolerance with lower or similar levels of insulin have been reported in more than ten
trials of chromium supplementation in people with varying degrees of glucose
intolerance.83 Chromium supplements improve glucose tolerance in people with type 2
diabetes,84 apparently by increasing sensitivity to insulin.85 Chromium improves the processing
of glucose in people with prediabetic glucose intolerance and in women with diabetes
associated with pregnancy.86
87 Chromium even helps healthy people,88 although one such report found
chromium useful only when accompanied by 100 mg of niacin per day.89 Chromium may also lower
levels of total cholesterol, LDL cholesterol,
and triglycerides (risk factors in heart disease).90 91
A few trials have reported no beneficial effects from chromium
supplementation.92 93 94 All of these trials used 200 mcg or
less of supplemental chromium, which is often not adequate for people with diabetes,
especially if it is in a form that is poorly absorbed. The typical amount of chromium used in
research trials is 200 mcg per day, although as much as 1,000 mcg per day has been
used.95 Many doctors recommend up to 1,000 mcg per day for people with
diabetes.96
Supplementation with chromium or brewer’s yeast could potentially enhance the effects
of drugs used for diabetes (e.g., insulin or other blood sugar-lowering agents) and possibly
lead to hypoglycemia. Therefore, people with
diabetes taking these medications should supplement with chromium or brewer’s yeast only
under the supervision of a doctor.
Magnesium
People with type 2 diabetes tend to have low magnesium levels.97 Double-blind
research indicates that supplementing with magnesium overcomes this problem.98
Magnesium supplementation has improved insulin production in elderly people with type 2
diabetes.99 However, one double-blind trial found no effect from 500 mg magnesium
per day in people with type 2 diabetes, although twice that amount led to some
improvement.100 Elders without diabetes can also produce more insulin as a result
of magnesium supplements, according to some,101 but not all, trials.102
However, in people with type 2 diabetes who nonetheless require insulin, Dutch researchers
have reported no improvement in blood sugar levels from magnesium
supplementation.103 The American Diabetes Association acknowledges strong
associations between magnesium deficiency and insulin resistance but has not said magnesium
deficiency is a risk factor104 Many doctors, however, recommend that people with
diabetes and normal kidney function supplement with 200 to 600 mg of magnesium per day.
Diabetes-induced damage to the eyes is more likely to occur in magnesium-deficient people
with type 1 diabetes.105 In magnesium-deficient pregnant women with type 1 diabetes, the lack of
magnesium may even account for the high rate of spontaneous abortion and birth defects associated with type 1
diabetes.106 The American Diabetes Association admits “strong
associations...between magnesium deficiency and insulin resistance” but will not say
magnesium deficiency is a risk factor.107 Many doctors, however, recommend that
people with diabetes and normal kidney function supplement with 200–600 mg of magnesium
per day.
Alpha lipoic
acid
Alpha lipoic acid is a powerful natural
antioxidant. Preliminary and double-blind trials have found that supplementing 600 to
1,200 mg of lipoic acid per day improves insulin sensitivity and the symptoms of diabetic
neuropathy.108 109 110 111 112
113 114 115 In a preliminary study, supplementing with 600 mg of
alpha lipoic acid per day for 18 months slowed the progression of kidney damage in patients
with type 2 diabetes.116
Evening primrose
oil
Supplementing with 4 grams of evening primrose oil per day for six months has been found in
double-blind research to improve nerve function and to relieve pain symptoms of diabetic
neuropathy.117
Glucomannan
Glucomannan is a water-soluble dietary fiber derived from konjac root (Amorphophallus
konjac)that delays stomach emptying, leading to a more gradual absorption of dietary
sugar. This effect can reduce the elevation of blood sugar levels that is typical after a
meal. 118 After-meal blood sugar levels are lower in people with diabetes given
glucomannan in their food, 119 and overall diabetic control is improved with
glucomannan-enriched diets, according to preliminary and controlled clinical trials.
120 121 122 One preliminary report suggested that glucomannan may
also be helpful in pregnancy-related diabetes. 123 For controlling blood sugar, 500
to 700 mg of glucomannan per 100 calories in the diet has been used successfully in controlled
research.
Vitamin
E
People with low blood levels of vitamin E are more likely to develop type 1 and type 2
diabetes.124 125 Vitamin E supplementation has improved glucose
tolerance in people with type 2 diabetes in most,126 127 128
but not all,129 double-blind trials. Vitamin E has also improved glucose tolerance
in elderly people without diabetes.130 131 Three months or more of at
least 900 IU of vitamin E per day may be required for benefits to become apparent.
In one of the few trials to find vitamin E supplementation ineffective for glucose
intolerance in people with type 2 diabetes, damage to nerves caused by the diabetes was
nonetheless partially reversed by supplementing with vitamin E for six months.132
Animal and preliminary human data indicate that vitamin E supplementation may protect against
diabetic retinopathy and
nephropathy,133 134 serious complications of diabetes involving the eyes
and kidneys, respectively, though no long-term trials in humans have confirmed this
preliminary evidence.
Glycosylation is an important measurement of diabetes; it refers to how much sugar attaches
abnormally to proteins. Excessive glycosylation appears to be one of the causes of the organ
damage that occurs in diabetes. Vitamin E supplementation has reduced the amount of
glycosylation in many,135 136 137 138
139 although not all,140 141 142 studies.
In one report, vitamin E was found to impair glucose tolerance in obese patients with diabetes.143 The reason
for the discrepancy between reports is not known.
Vitamin E appears to lower the risk of cerebral infarction, a type of stroke, in people with diabetes who smoke. A review of
a large Finnish study of smokers concluded that smokers with diabetes (or hypertension) can benefit from small amounts of
vitamin E (50 IU per day).144
Vitamin
C
As with vitamin E, vitamin C may reduce glycosylation.145 Vitamin C also lowers
sorbitol levels in people with diabetes.146 Sorbitol is a sugar that can accumulate
inside the cells and damage the eyes, nerves, and kidneys of people with diabetes. Vitamin C
may improve glucose tolerance in type 2 diabetes,147 148 although not
every study confirms this benefit.149 Vitamin C supplementation (500 mg twice a day
for one year) has significantly reduced urinary protein loss in people with diabetes. Urinary
protein loss (also called proteinuria) is associated with poor prognosis in
diabetes.150 Many doctors suggest that people with diabetes supplement with 1 to 3
grams per day of vitamin C. Higher amounts could be problematic, however. In one person, 4.5
grams per day was reported to increase blood sugar levels.151
One study examined antioxidant supplement intake, including both vitamins E and C, and the
incidence of diabetic retinopathy (damage to
the eyes caused by diabetes).152 Surprisingly, people with extensive retinopathy
had a greater likelihood of having taken vitamin C and vitamin E supplements. The
outcome of this trial, however, does not fit with most other published data and might simply
reflect the fact that sicker people are more likely to take supplements in hopes of getting
better. For the present, most doctors remain relatively unconcerned about the outcome of this
isolated report.
B Vitamins
Many people with diabetes have low blood levels of vitamin B6.153 154 Levels are
even lower in people with diabetes who also have nerve damage (neuropathy).155
Vitamin B6 supplementation has improved glucose tolerance in women with diabetes caused by
pregnancy.156 157 Vitamin B6 supplementation is also effective for
glucose intolerance induced by birth control
pills.158 In a trial that included people with type 2 diabetes, 1,800 mg per
day of a special form of vitamin B6—pyridoxine alpha-ketoglutarate—improved
glucose tolerance dramatically.159 Standard vitamin B6 has helped in
some,160 but not all, trials.161
A controlled trial in Africa found that supplementing with both vitamin B1 (25 mg per day)
and vitamin B6 (50 mg per day) led to
significant improvement of symptoms of diabetic neuropathy after four weeks.162
However, since this was a trial conducted among people in a vitamin B1–deficient
developing country, these improvements might not occur in other people with diabetes. Another
trial found that combining vitamin B1 (in a special fat-soluble form) and vitamin B6 plus vitamin B12 in high but variable amounts led to
improvement in some aspects of diabetic neuropathy in 12 weeks.163 As a result,
some doctors recommend that people with diabetic neuropathy supplement with vitamin B1, though
the optimal level of intake remains unknown.
Biotin is a B vitamin needed to process
glucose. When people with type 2 diabetes were given 9 mg of biotin per day for two months,
their fasting glucose levels dropped dramatically.164 Biotin may also reduce pain from diabetic nerve damage.165
Some doctors try 9 to 16 mg of biotin per day for a few weeks to see if blood sugar levels
will fall.
Vitamin B12 is needed for normal
functioning of nerve cells. Vitamin B12 taken orally has reduced symptoms of nerve damage
caused by diabetes in 39% of people studied; when given both intravenously and orally,
two-thirds of people improved.166 In a preliminary trial, people with nerve damage
due to kidney disease or to diabetes plus kidney disease received intravenous injections of
500 mcg of methylcobalamin (the main form of vitamin B12 found in the blood) three times a day
for six months in addition to kidney dialysis. Nerve pain was significantly reduced and nerve
function significantly improved in those who received the injections.167 Oral
vitamin B12 up to 500 mcg three times per day is recommended by some practitioners.
The intake of large amounts of niacin (a
form of vitamin B3), such as 2 to 3 grams per day, may impair glucose tolerance and should be
used by people with diabetes only with medical supervision.168 169
Smaller amounts (500 to 750 mg per day for one month followed by 250 mg per day) may help some
people with type 2 diabetes,170 though this research remains preliminary.
Coenzyme
Q10
Coenzyme Q10 (CoQ10) is needed for normal blood sugar metabolism. Animals with diabetes have
been reported to be CoQ10 deficient. People with type 2 diabetes have been found to have
significantly lower blood levels of CoQ10 compared with healthy people.171 In one
trial, blood sugar levels fell substantially in 31% of people with diabetes after they
supplemented with 120 mg per day of CoQ7, a substance similar to CoQ10.172 The
importance of CoQ10 supplementation for people with diabetes remains an unresolved issue,
though some doctors recommend approximately 50 mg per day as a way to protect against possible
effects associated with diabetes-induced depletion.
L-carnitine
L-carnitine is an amino acid needed to
properly utilize fat for energy. When people with diabetes were given DL-carnitine (0.5 mg per
2.2 pounds of body weight), high blood levels of fats—both cholesterol and triglycerides—dropped 25 to 39% in just ten days
in one trial.173
Acetyl-L-carnitine
In a double-blind study of people with diabetic neuropathy, supplementing with
acetyl-L-carnitine was significantly more effective than a placebo in improving subjective
symptoms of neuropathy and objective measures of nerve function.174 People who
received 1,000 mg of acetyl-L-carnitine three times per day tended to fare better than those
who received 500 mg three times per day.
Zinc
People with type 2 diabetes tend to be zinc deficient,175 but some evidence
indicates that zinc supplementation does not improve their ability to process
sugar.176 Nonetheless, many doctors recommend that people with type 2 diabetes
supplement with moderate amounts of zinc (15 to 25 mg per day) as a way to correct the
deficit.
Antioxidants
Because oxidation damage is believed to play a role in the development of diabetic
retinopathy, antioxidant nutrients might be protective. One doctor has administered a daily
regimen of 500 mcg selenium, 800 IU vitamin E, 10,000 IU vitamin A, and 1,000 mg vitamin C for several years to 20 people with diabetic
retinopathy. During that time, 19 of the 20 people showed either improvement or no progression
of their retinopathy.177 People who wish to supplement with more than 250 mcg of
selenium per day should consult a healthcare practitioner.
Vitamin
D
Vitamin D is needed to maintain adequate blood levels of insulin.178 Vitamin D
receptors have been found in the pancreas where insulin is made, and preliminary evidence
suggests that supplementation can improve some measures of blood sugar control in people with
type 2 diabetes.179 180 Not enough is known about optimal amounts of
vitamin D for people with diabetes, and high amounts of vitamin D can be toxic; therefore,
people with diabetes considering vitamin D supplementation should talk with a doctor and have
their vitamin D status assessed.
Inositol
Inositol is needed for normal nerve function. Diabetes can cause a type of nerve damage known
as diabetic neuropathy. This condition has been reported in some, but not all, trials to
improve with inositol supplementation (500 mg taken twice per day).181
Taurine
Animal studies have shown that supplementing with taurine, an amino acid found in protein-rich
food, may affect insulin secretion and action, and may have potential in protecting the eyes
and nerves from diabetic complications.182 However, a double-blind trial found no
effect on insulin secretion or sensitivity when men with high risk for developing diabetes
were given 1.5 grams per day of taurine for eight weeks.183 In another double-blind
trial, taurine supplementation (2 grams per day for 12 months) failed to improve kidney
complications associated with type 2 diabetes.184
Fish
oil
Glucose tolerance improves in healthy people taking omega-3 fatty acid
supplements,185 and some studies have found that fish oil supplementation also
improves glucose tolerance,186 high
triglycerides,187 and
cholesterol levels in people with type 2 diabetes.188 And in one trial, people
with diabetic neuropathy and diabetic nephropathy experienced significant improvement when
given 600 mg three times per day of purified eicosapentaenoic acid (EPA)—one of the two
major omega-3 fatty acids found in fish oil supplements—for 48 weeks.189
However, other studies have found that type 2 diabetes worsens with fish oil
supplementation.190 191 192 193 Until this issue
is resolved, people with diabetes should feel free to eat fish, but they should consult a
doctor before taking fish oil supplements.
Quercetin
Doctors have suggested that quercetin might help people with diabetes because of its ability
to reduce levels of sorbitol—a sugar
that accumulates in nerve cells, kidney cells, and cells within the eyes of people with
diabetes—and has been linked to damage to those organs.194 Clinical trials
have yet to explore whether quercetin actually protects people with diabetes from neuropathy,
nephropathy, or retinopathy.
Vanadium
Vanadyl sulfate, a form of vanadium, may improve glucose control in people with type 2
diabetes.195 196 197 Over a six-week period, a small group of
people with type 2 diabetes were given 75 to 300 mg of vanadyl sulfate per day.198
Only in the groups receiving 150 mg or 300 mg was glucose metabolism improved, fasting blood
sugar decreased, and another marker for chronic high blood sugar reduced. At the 300 mg level,
total cholesterol decreased, although not without an accompanying reduction in the protective
HDL cholesterol. None of the amounts improved insulin sensitivity. Although there was no
evidence of toxicity after six weeks of vanadyl sulfate supplementation, gastrointestinal side
effects were experienced by some of the participants taking 150 mg per day and by all of the
participants taking 300 mg per day. The long-term safety of the large amounts of vanadium
needed to help people with type 2 diabetes (typically 100 mg per day) remains unknown. Many
doctors expect that amounts this high may prove to be unsafe in the long term.
Fructo-oligosaccharides
In a preliminary trial, supplementation with fructo-oligosaccharides (FOS) (8 grams per day
for two weeks) significantly lowered fasting blood-sugar levels and serum total-cholesterol
levels in people with type 2 diabetes.199 However, in another trial, supplementing
with FOS (15 grams per day) for 20 days had no effect on blood-glucose or lipid levels in
people with type 2 diabetes.200 In addition, some double-blind trials showed that
supplementing with FOS or galacto-oligosaccharides (GOS) for eight weeks had no effect on
blood-sugar levels, insulin secretion, or blood lipids in healthy people.201
202 Because of these conflicting results, more research is needed to determine the
effect of FOS on diabetes and lipid levels.
Manganese
People with diabetes may have low blood levels of manganese.203 Animal research
suggests that manganese deficiency can contribute to glucose intolerance and may be reversed
by supplementation.204 A young adult with insulin-dependent diabetes who received
oral manganese chloride (3 to 5 mg per day as manganese chloride) reportedly experienced a
significant fall in blood glucose, sometimes to dangerously low levels. In four other cases,
manganese supplementation had no effect on blood glucose levels.205 People with
diabetes wishing to supplement with manganese should do so only with a doctor’s
supervision.
Medium-chain
triglycerides
Based on the results of a short-term clinical trial that found that medium-chain triglycerides
(MCT) lower blood glucose levels,206 a group of researchers investigated the use of
MCT to treat people with type 2 diabetes mellitus. Supplementation with MCT for an average of
17.5% of their total calorie intake for 30 days failed to improve most measures of diabetic
control.207
Starch
blockers
Starch blockers are substances that inhibit amylase, the digestive enzyme required to break
down dietary starches for normal absorption. Controlled research has demonstrated that
concentrated starch blocker extracts, when given with a starchy meal, can reduce the usual
rise in blood sugar levels of both healthy people and diabetics.208 209
210 211 212 While this effect could be helpful in controlling
diabetes, no research has investigated the long-term effects of taking starch blockers for
this condition.
Are there any side effects or interactions?
Refer to the individual supplement for information about any side effects or interactions.
1. Hoogeveen EK, Kostense PJ, Jakobs C, et al. Hyperhomocysteinemia
increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study.
Circulation 2000;101:1506–11.
2. Colditz GA, Manson JE, Stampfer MJ, et al. Diet and risk of clinical
diabetes in women. Am J Clin Nutr 1992;55:1018–23.
3. Feskens EJ, Bowles CH, Kromhout D. Carbohydrate intake and body mass
index in relation to the risk of glucose intolerance in an elderly population. Am J Clin
Nutr 1991;54:136–40.
4. Wright DW, Hansen RI, Mondon CE, Reaven GM. Sucrose-induced insulin
resistance in the rat: modulation by exercise and diet. Am J Clin Nutr
1983;38:879–83.
5. Reiser S, Hallfrisch J, Fields M, et al. Effects of sugars on indices
of glucose tolerance in humans. Am J Clin Nutr 1986;43:151–9.
6. Wolever TMS, Brand Miller J. Sugars and blood glucose control. Am
J Clin Nutr 1995;62:212S–7S [review].
7. Wolever TMS, Brand Miller J. Sugars and blood glucose control. Am
J Clin Nutr 1995;62:212S–7S [review].
8. Salmeron J, Manson JE, Stampfer MJ, et al. Dietary fiber, glycemic
load, and risk of non-insulin-dependent diabetes mellitus in women. JAMA
1997;277:472–7.
9. Salmeron J, Ascherio A, Rimm EB, et al. Dietary fiber, glycemic load,
and risk of NIDDM in men. Diabetes Care 1997;20:545–50.
10. Feskens EJ, Virtanen SM, Rasanen L, et al. Dietary factors
determining diabetes and impaired glucose tolerance. A 20-year follow-up of the Finnish and
Dutch cohorts of the Seven Countries Study. Diabetes Care 1995;18:1104–12.
11. Salmeron J, Manson JE, Stampfer MJ, et al. Dietary fiber, glycemic
load, and risk of non-insulin-dependent diabetes mellitus in women. JAMA
1997;277:472–7.
12. Salmeron J, Ascherio A, Rimm EB, et al. Dietary fiber, glycemic load,
and risk of NIDDM in men. Diabetes Care 1997;20:545–50.
13. Colagiuri S, Miller JJ, Edwards RA. Metabolic effects of adding
sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus.
Am J Clin Nutr 1989;50:474–8.
14. Abraira C, Derler J. Large variations of sucrose in constant
carbohydrate diets in type II diabetes. Am J Med 1988;84:193–200.
15. Loghmani E, Rickard K, Washburne L, et al. Glycemic response to
sucrose-containing mixed meals in diets of children with insulin-dependent diabetes mellitus.
J Pediatr 1991;119:531–7.
16. American Diabetes Association. Position Statement: nutrition
recommendations and principles for people with diabetes mellitus. Diabetes Care
1999;22:S42–5 [review].
17. Brand-Miller J, Foster-Powell K. Diets with a low glycemic index:
from theory to practice. Nutr Today 1999;34:64–72 [review].
18. Chandalia M, Garg A, Lutjohann D, et al. Beneficial effects of high
dietary fiber intake in patients with type 2 diabetes mellitus. New Engl J Med
2000;342:1392–8.
19. Rodríguez-Morán M, Guerrero-Romero F, Lazcano-Burciaga G.
Lipid- and glucose-lowering efficacy of plantago psyllium in type II diabetes. Diabetes
Its Complications 1998;12:273–8.
20. Landin K, Holm G, Tengborn L, Smith U. Guar gum improves insulin
sensitivity, blood lipids, blood pressure, and fibrinolysis in healthy men. Am J Clin
Nutr 1992;56:1061–5.
21. Schwartz SE, Levine RA, Weinstock RS, et al. Sustained pectin
ingestion: effect on gastric emptying and glucose tolerance in non-insulin-dependent diabetic
patients. Am J Clin Nutr 1988;48:1413–7.
22. Hallfrisch J, Scholfield DJ, Behall KM. Diets containing soluble oat
extracts improve glucose and insulin responses of moderately hypercholesterolemic men and
women. Am J Clin Nutr 1995;61:379–84.
23. Doi K, Matsuura M, Kawara A, Baba S. Treatment of diabetes with
glucomannan (konjac mannan). Lancet 1979;1:987–8 [letter].
24. Vuksan V, Sievenpiper JL, Owen R, et al. Beneficial effects of
viscous dietary fiber from Konjac-mannan in subjects with the insulin resistance syndrome:
results of a controlled metabolic trial. Diabetes Care 2000;23:9–14.
25. Sharma RD, Raghuram TC. Hypoglycaemic effect of fenugreek seeds in
non-insulin dependent diabetic subjects. Nutr Res 1990;10:731–9.
26. Raghuram TC, Sharma RD, Sivakumar B, Sahay BK. Effect of fenugreek
seeds on intravenous glucose disposition in non-insulin dependent diabetic patients.
Phytother Res 1994;8:83–6.
27. Nuttall FW. Dietary fiber in the management of diabetes.
Diabetes 1993;42:503–8.
28. Feskens EJM, Bowles CH, Kromhout D. Inverse association between fish
intake and risk of glucose intolerance in normoglycemic elderly men and women. Diabetes
Care 1991;14:935–41.
29. Mori TA, Bao DQ, Burke V, et al. Dietary fish as a major component of
a weight-loss diet: effect on serum lipids, glucose, and insulin metabolism in overweight
hypertensive subjects. Am J Clin Nutr 1999;70:817–25.
30. Snowdon DA, Phillips RL. Does a vegetarian diet reduce the occurrence
of diabetes? Am J Publ Health 1985;75:507–12.
31. Crane MG, Sample CJ. Regression of diabetic neuropathy with vegan
diet. Am J Clin Nutr 1988;48:926 [abstract #P28].
32. Crane MG, Sample C. Regression of diabetic neuropathy with total
vegetarian (vegan) diet. J Nutr Med 1994;4:431–9.
33. Cohen D, Dodds R, Viberti G. Effect of protein restriction in insulin
dependent diabetics at risk of nephropathy. BMJ 1987;294:795–8.
34. Evanoff G, Thompson C, Bretown J, Weinman E. Prolonged dietary
protein restriction in diabetic nephropathy. Arch Intern Med
1989;149:1129–33.
35. Gin H, Aparicio M, Potauz L, et al. Low-protein, low-phosphorus diet
and tissue insulin sensitivity in insulin-dependent diabetic patients with chronic renal
failure. Nephron 1991;57:411–5.
36. Baba NH, Sawaya S, Torbay N, et al. High protein vs high carbohydrate
hypoenergetic diet for the treatment of obese hyperinsulinemic subjects. Int J Obes Relat
Metab Disord 1999;23:1202–6.
37. Feskens EJ, Virtanen SM, Rasanen L, et al. Dietary factors
determining diabetes and impaired glucose tolerance. A 20-year follow-up of the Finnish and
Dutch cohorts of the Seven Countries Study. Diabetes Care 1995;18:1104–12.
38. Feskens EJ, Kromhout D. Habitual dietary intake and glucose tolerance
in euglycaemic men: the Zutphen Study. Int J Epidemiol 1990;19:953–9.
39. Marshall JA, Hoag S, Shetterly S, et al. Dietary fat predicts
conversion from impaired glucose tolerance to NIDDM. The San Luis Valley Diabetes Study.
Diabetes Care 1994;17:50–6.
40. Marshall JA, Hamman RF, Baxter J. High-fat, low-carbohydrate diet and
the etiology of non-insulin-dependent diabetes mellitus: the San Luis Valley Diabetes Study.
Am J Epidemiol 1991;134:590–603.
41. Uusitupa M, Schwab U, Makimattila S, et al. Effects of two high-fat
diets with different fatty acid compositions on glucose and lipid metabolism in healthy young
women. Am J Clin Nutr 1994;59:1310–6.
42. Sarkkinen E, Schwab U, Niskanen L, et al. The effects of
monounsaturated-fat enriched diet and polyunsaturated-fat enriched diet on lipid and glucose
metabolism in subjects with impaired glucose tolerance. Eur J Clin Nutr
1996;50:592–8.
43. Garg A, Bananome A, Grundy SM, et al. Comparison of a
high-carbohydrate diet with a high-monounsaturated-fat diet in patients with non-insulin
dependent diabetes mellitus. N Engl J Med 1988;319:829–34.
44. Isida K, Mizuno A, Murakami T, Shima K. Obesity is necessary but not
sufficient for the development of diabetes mellitus. Metabolism
1996;45:1288–95.
45. Casassus P, Fontbonne A, Thibult N, et al. Upper-body fat
distribution: a hyperinsulinemia-independent predictor of coronary heart disease mortality.
Arterioscler Thromb 1992;1387–92.
46. Karter AJ, Mayer-Davis EJ, Selby JV, et al. Insulin sensitivity and
abdominal obesity in African-American, Hispanic, and non-Hispanic white men and women.
Diabetes 1996;45:1547–55.
47. Park KS, Hree BD, Lee K-U, et al. Intra-abdominal fat is associated
with decreased insulin sensitivity in healthy young men. Metabolism
1991;40:600–3.
48. Long SD, Swanson MS, O’Brien K, et al. Weight loss in severely
obese subjects prevents the progression of impaired glucose tolerance to type II diabetes.
Diabetes Care 1994;17:372.
49. Pi-Sunyer FX. Weight and non-insulin-dependent diabetes mellitus.
Am J Clin Nutr 1996;63(suppl):426S–9S.
50. Wing RR, Marcuse MD, Blair EH, et al. Caloric restriction per se is a
significant factor in improvements in glycemic control and insulin sensitivity during weight
loss in obese NIDDM patients. Diabetes Care 1994;17:30.
51. Henry RR, Gumbiner B. Benefits and limitations of very-low-calorie
diet therapy in obese NIDDM. Diabetes Care 1991;14:802–23.
52. Hersey WC, Graves JE, Pollock ML, et al. Endurance exercise training
improves body composition and plasma insulin responses in 70- to 79-year-old men and women.
Metabol 1994;43:847–54.
53. Rasmussen OW, Lauszus FF, Hermansen K. Effects of postprandial
exercise on glycemic response in IDDM subjects. Diabetes Care 1994;17:1203.
54. Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS. Physical activity
and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med
1991;325:147–52.
55. (REF:Bell DSH. Exercise for patients with diabetes—benefits,
risks, precautions. Postgrad Med 1992;92:183–96 [review].
56. Kiechl S, Willeit J, Poewe W, et al. Insulin sensitivity and regular
alcohol consumption: large, prospective, cross sectional population study Bruneck study.
BMJ 1996;313:1040–4.
57. Facchini F, Chen Y-DI, Reaven GM. Light-to-moderate alcohol intake is
associated with enhanced insulin sensitivity. Diabetes Care 1994;17:115.
58. Rimm EB, Chan J, Stampfer MJ, et al. Prospective study of cigarette
smoking, alcohol use, and the risk of diabetes in men. BMJ 1995;310:555–9.
59. Stampfer MJ, Colditz GA, Willett WC, et al. A prospective study of
moderate alcohol drinking and risk of diabetes in women. Am J Epidemiol
1988;128:549–58.
60. Goden G, Chen X, Desantis R, et al. Effects of ethanol on
carbohydrate metabolism in the elderly. Diabetes 1993;42:28–34.
61. Ben G, Gnudi L, Maran A, et al. Effects of chronic alcohol intake on
carbohydrate and lipid metabolism in subjects with type II (non-insulin-dependent) diabetes.
Am J Med 1991;90:70.
62. Young RJ, McCulloch DK, Prescott RJ, Clarke PF. Alcohol: another risk
factor for diabetic retinopathy? BMJ 1984;288:1035.
63. Connor H, Marks V. Alcohol and diabetes. A position paper prepared by
the Nutrition Subcommittee of the British Diabetic Association’s Medical Advisory
Committee and approved by the Executive Council of the British Diabetic Association. Human
Nutr Appl Nutr 1985;39A:393–9.
64. Ajani UA, Hennekens CH, Spelsberg A, Manson JE. Alcohol consumption
and risk of type 2 diabetes mellitus among US male physicians. Arch Intern Med
2000;160:1025–30.
65. Wei M, Gibbons LW, Mitchell TL, et al. Alcohol intake and incidence
of type 2 diabetes in men. Diabetes Care 2000;23:18–22.
66. Valmadrid CT, Klein R, Moss SE, et al. Alcohol intake and the risk of
coronary heart disease mortality in persons with older-onset diabetes mellitus. JAMA
1999;282:239–46.
67. Wei M, Gibbons LW, Mitchell TL, et al. Alcohol intake and incidence
of type 2 diabetes in men. Diabetes Care 2000;23:18–22.
68. Stegmayr B, Lithner F. Tobacco and end stage diabetic nephropathy.
BMJ 1987;295:581–2.
69. Scala C, LaPorte RE, Dorman JS, et al. Insulin-dependent diabetes
mellitus mortality—the risk of cigarette smoking.
Circulation1990;82:37–43.
70. Rimm EB, Manson JE, Stampfer MJ, et al. Cigarette smoking and the
risk of diabetes in women. Am J Public Health 1993;83:211–4.
71. Rindone JP, Austin M, Luchesi J. Effect of home blood glucose
monitoring on the management of patients with non-insulin dependent diabetes mellitus in the
primary care setting. Am J Manag Care 1997;3:1335–8.
72. Faas A, Schellevis FG, Van Eijk JT. The efficacy of self-monitoring
of blood glucose in NIDDM subjects. A criteria-based literature review. Diabetes Care
1997;20:1482–6.
73. [No authors listed.] Position statement: Tests of glycemia in
diabetes. American Diabetes Association. Diabetes Care 2000;23(Suppl
1):S80–2.
74. Goldstein DE, Little RR, Lorenz RA, et al. Tests of glycemia in
diabetes. Diabetes Care 1995;18:896–909 [review].
75. Gallichan M. Self monitoring of glucose by people with diabetes:
evidence based practice. BMJ 1997;314:964–7 [review].
76. Steel LG. Identifying technique errors. Self-monitoring of blood
glucose in the home setting. J Gerontol Nurs 1994;20:9–12.
77. Foster SA, Goode JV, Small RE. Home blood glucose monitoring. Ann
Pharmacother 1999;33:355–63 [review].
78. Barringer TA, Kirk JK, Santaniello AC, et al. Effect of a
multivitamin and mineral supplement on infection and quality of life. A randomized,
double-blind, placebo-controlled trial. Ann Intern Med 2003;138:365–71.
79. Herepath WB. Journal Provincial Med Surg Soc 1854:374.
80. Offenbacher EG, Pi-Sunyer FX. Beneficial effect of chromium-rich
yeast on glucose tolerance and blood lipids in elderly subjects. Diabetes
1980;29:919–25.
81. Anderson RA. Chromium in the prevention and control of diabetes.
Diabetes Metab 2000;26:22–7 [review].
82. Martin J, Wang ZQ, Zhang XH, et al. Chromium picolinate
supplementation attenuates body weight gain and increases insulin sensitivity in subjects with
type 2 diabetes. Diabetes Care 2006;29:1826–32.
83. Anderson RA. Chromium, glucose intolerance and diabetes. J Am
Coll Nutr 1998;17:548–55 [review].
84. Evans GW. The effect of chromium picolinate on insulin controlled
parameters in humans. Int J Biosocial Med Res 1989;11:163–80.
85. Gaby AR, Wright JV. Diabetes. In Nutritional Therapy in Medical
Practice: Reference Manual and Study Guide. Kent, WA: 1996, 54–64 [review].
86. Anderson RA, Polansky MM, Bryden NA, Canary JJ. Supplemental-chromium
effects on glucose, insulin, glucagon, and urinary chromium losses in subjects consuming
controlled low-chromium diets. Am J Clin Nutr 1991;54:909–16.
87. Jovanovic L, Gutierrez M, Peterson CM. Chromium supplementation for
women with gestational diabetes. J Trace Elem Exptl Med 1999;12:91–8.
88. Anderson RA, Polansky MM, Bryden NA, et al. Chromium supplementation
of human subjects: effects on glucose, insulin, and lipid variables. Metabolism
1983;32:894–9.
89. Urberg M, Zemel MB. Evidence for synergism between chromium and
nicotinic acid in the control of glucose tolerance in elderly humans. Metabolism
1987;36:896–9.
90. Lee NA, Reasner CA. Beneficial effect of chromium supplementation on
serum triglyceride levels in NIDDM. Diabetes Care 1994;17:1449–52.
91. Hermann J, Chung H, Arquitt A, et al. Effects of chromium or copper
supplementation on plasma lipids, plasma glucose and serum insulin in adults over age fifty.
J Nutr Elderly 1998;18:27–45.
92. Sherman L, Glennon JA, Brech WJ, et al. Failure of trivalent chromium
to improve hyperglycemia in diabetes mellitus. Metabolism 1968;17:439–42.
93. Rabinowitz MB, Gonick HC, Levin SR, Davidson MB. Effects of chromium
and yeast supplements on carbohydrate and lipid metabolism in diabetic men. Diabetes
Care 1983;6:319–27.
94. Uusitupa MI, Kumpulainen JT, Voutilainen E, et al. Effect of
inorganic chromium supplementation on glucose tolerance, insulin response, and serum lipids in
noninsulin-dependent diabetics. Am J Clin Nutr 1983;38:404–10.
95. Anderson RA, Cheng N, Bryden NA, et al. Elevated intakes of
supplemental chromium improve glucose and insulin variables in individuals with type 2
diabetes. Diabetes 1997;46:1786–91.
96. Gaby AR, Wright JV. Nutritional protocols: diabetes mellitus. In
Nutritional Therapy in Medical Practice: Protocols and Supporting Information. Kent, WA:
1996, 10.
97. Paolisso G, Scheen A, D’Onofrio FD, Lefebvre P. Magnesium and
glucose homeostasis. Diabetologia 1990;33:511–4 [review].
98. Eibl NL, Schnack CJ, Kopp H-P, et al. Hypomagnesemia in type II
diabetes: effect of a 3-month replacement therapy. Diabetes Care 1995;18:188.
99. Paolisso G, Sgambato S, Pizza G, et al. Improved insulin response and
action by chronic magnesium administration in aged NIDDM subjects. Diabetes Care
1989;12:265–9.
100. Lima M, Cruz T, Carreiro Pousada J, et al: The effect of magnesium
supplementation in increasing doses on the control of type 2 diabetes. Diabetes Care
1998;21:682–6.
101. Paolisso G, Sgambato S, Gambardella A, et al. Daily magnesium
supplements improve glucose handling in elderly subjects. Am J Clin Nutr
1992;55:1161–7.
102. Smellie WS, O’Reilly DS, Martin BJ, Santamaria J. Magnesium
replacement and glucose tolerance in elderly subjects. Am J Clin Nutr
1993;57:594–6 [letter].
103. de Valk HW, Verkaaik R, van Rijn HJM, et al. Oral magnesium
supplementation in insulin-requiring type 2 diabetic patients. Diabet Med
1998;15:503–7.
104. American Diabetes Association. Magnesium supplementation in the
treatment of diabetes. Diabetes Care 1992;15:1065–7.
105. McNair P, Christiansen C, Madsbad S, et al. Hypomagnesemia, a risk
factor in diabetic retinopathy. Diabetes 1978;27:1075–7.
106. Mimouni F, Miodovnik M, Tsang RC, et al. Decreased maternal serum
magnesium concentration and adverse fetal outcome in insulin-dependent diabetic women.
Obstet Gynecol 1987;70:85–9.
107. American Diabetes Association. Magnesium supplementation in the
treatment of diabetes. Diabetes Care 1992;15:1065–7.
108. Konrad T, Vicini P, Kusterer K, et al. alpha lipoic acid treatment
decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean
and obese patients with type 2 diabetes. Diabetes Care 1999;22:280–7.
109. Ruhnau KJ, Meissner HP, Finn JR, et al. Effects of 3-week oral
treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic
polyneuropathy. Diabet Med 1999;16:1040–3.
110. Ruhnau KJ, Meissner HP, Finn JR, et al. Effects of 3-week oral
treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic
polyneuropathy. Diabet Med 1999;16:1040–3.
111. Reljanovic M, Reichel G, Rett K, et al. Treatment of diabetic
polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter
randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic
Neuropathy. Free Radic Res 1999;31:171–9.
112. Ziegler D, Schatz H, Conrad F, et al. Effects of treatment with the
antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month
randomized controlled multicenter trial (DEKAN Study). Diabetes Care
1997;20:369–73.
113. Jacob S, Ruus P, Hermann R, et al. Oral administration of
RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus:
a placebo-controlled pilot trial. Free Radic Biol Med 1999;27:309–14.
114. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic
diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter
randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in
Diabetic Neuropathy. Diabetes Care 1999;22:1296–301.
115. Ziegler D, Ametov A, Barinov A, et al. Oral treatment with
alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial.
Diabetes Care 2006;29:2365–70.
116. Morcos M, Borcea V, Isermann B, et al. Effect of alpha-lipoic acid
on the progression of endothelial cell damage and albuminuria in patients with diabetes
mellitus: an exploratory study. Diabetes Res Clin Pract 2001;52:175–83.
117. Jamal GA, Carmichael H. The effect of gamma-linolenic acid on human
diabetic peripheral neuropathy: a double-blind placebo-controlled trial. Diabet Med
1990;7:319–23.
118. Doi K. Effect of konjac fibre (glucomannan) on glucose and lipids.
Eur J Clin Nutr 1995;49(Suppl. 3):S190–7 [review].
119. Melga P, Giusto M, Ciuchi E, et al. Dietary fiber in the dietetic
therapy of diabetes mellitus. Experimental data with purified glucomannans. Riv Eur Sci
Med Farmacol 1992;14:367–73 [in Italian].
120. Huang CY, Zhang MY, Peng SS, et al. Effect of Konjac food on blood
glucose level in patients with diabetes. Biomed Environ Sci 1990;3:123–31.
121. Vuksan V, Jenkins DJ, Spadafora P, et al. Konjac-mannan
(glucomannan) improves glycemia and other associated risk factors for coronary heart disease
in type 2 diabetes. A randomized controlled metabolic trial. Diabetes Care
1999;22:913–9.
122. Vorster HH, Lotter AP, Odendaal I, et al. Benefits from
supplementation of the current recommended diabetic diet with gel fibre. Int Clin Nutr
Rev 1988;8:140–6.
123. Cesa F, Mariani S, Fava A, et al. The use of vegetable fibers in the
treatment of pregnancy diabetes and/or excessive weight gain during pregnancy. Minerva
Ginecol 1990;42:271–4 [in Italian].
124. Knekt P, Reunanen A, Marniumi J, et al. Low vitamin E status is a
potential risk factor for insulin-dependent diabetes mellitus. J Intern Med
1999;245:99–102.
125. Salonen JT, Nyssonen K, Tuomainen T-P, et al. Increased risk of
non-insulin dependent diabetes mellitus at low plasma vitamin E concentrations: a four year
follow up study in men. BMJ 1995;311:1124–7.
126. Bierenbaum ML, Noonan FJ, Machlin LJ, et al. The effect of
supplemental vitamin E on serum parameters in diabetics, post coronary and normal subjects.
Nutr Rep Int 1985;31:1171–80.
127. Paolisso G, D’Amore A, Giugliano D, et al. Pharmacologic doses
of vitamin E improve insulin action in healthy subjects and non-insulin dependent diabetic
patients. Am J Clin Nutr 1993;57:650–6.
128. Paolisso G, D’Amore A, Galzerano D, et al. Daily vitamin E
supplements improve metabolic control but not insulin secretion in elderly type II diabetic
patients. Diabetes Care 1993;16:1433–7.
129. Tütüncü NB, Bayraktar M, Varli K. Reversal of
defective nerve condition with vitamin E supplementation in type 2 diabetes. Diabetes
Care 1998;21:1915–8.
130. Paolisso G, Di Maro G, Galzerano D, et al. Pharmacological doses of
vitamin E and insulin action in elderly subjects. Am J Clin Nutr
1994;59:1291–6.
131. Paolisso G, Gambardella A, Galzerano D, et al. Antioxidants in
adipose tissue and risk of myocardial infarction. Lancet 1994;343:596 [letter].
132. Tütüncü NB, Bayraktar M, Varli K. Reversal of
defective nerve condition with vitamin E supplementation in type 2 diabetes. Diabetes
Care 1998;21:1915–8.
133. Ross WM, Creighton MO, Stewart-DeHaan PJ, et al. Modelling cortical
cataractogenesis: 3. In vivo effects of vitamin E on cataractogenesis in diabetic rats.
Can J Ophthalmol 1982;17:61.
134. Bursell SE, Schlossman DK, Clermont AC, et al. High-dose vitamin E
supplementation normalizes retinal blood flow and creatinine clearance in patients with type I
diabetes. Diabetes Care 1999;22:1245–51.
135. Ceriello A, Giugliano D, Quatraro A, et al. Vitamin E reduction of
protein glycosylation in diabetes. Diabetes Care 1991;14:68–72.
136. Duntas L, Kemmer TP, Vorberg B, Scherbaum W. Administration of
d-alpha-tocopherol in patients with insulin-dependent diabetes mellitus. Curr Ther
Res 1996;57:682–90.
137. Paolisso G, D’Amore A, Galzerano D, et al. Daily vitamin E
supplements improve metabolic control but not insulin secretion in elderly type II diabetic
patients. Diabetes Care 1993;16:1433–7.
138. Jain SK, McVie R, Jaramillo JJ, et al. Effect of modest vitamin E
supplementation on blood glycated hemoglobin and triglyceride levels and red cell indices in
type I diabetic patients. J Am Coll Nutr 1996;15:458–61.
139. Jain SK, McVie R, Smith T. Vitamin E supplementation restores
glutathione and malondialdehyde to normal concentrations in erythrocytes of type 1 diabetic
children. Diabetes Care 2000;23:1389–94.
140. Reaven PD, Barnett J, Herold DA, Edelman S. Effect of vitamin E on
susceptibility of low-density lipoprotein and low-density lipoprotein subfractions to
oxidation and on protein glycation in NIDDM. Diabetes Care 1995;18:807.
141. Bursell S-E, Schlossman DK, Clermont AC, et al. High-dose vitamin E
supplementation normalizes retinal blood flow and creatineine clearance in patients with type
I diabetes. Diabetes Care 1999;22:1245–51.
142. Fuller CJ, Chandalia M, Garg A, et al. RRR-alpha-tocopheryl acetate
supplementation at pharmacologic doses decreases low-density-lipoprotein oxidative
susceptibility but not protein glycation in patients with diabetes mellitus. Am J Clin
Nutr 1996;63:753–9.
143. Skrha J, Sindelka G, Kvasnicka J, Hilgertova J. Insulin action and
fibrinolysis influenced by vitamin E in obese type 2 diabetes mellitus. Diabetes Res Clin
Pract 1999;44:27–33.
144. Leppälä JM, Virtamo J, Fogelholm R, et al. Vitamin E and
beta carotene supplementation in high risk for stroke: A subgroup analysis of the
alpha-tocopherol, beta-carotene cancer prevention study. Arch Neurol
2000;57:1503–9.
145. Davie SJ, Gould BJ, Yudkin JS. Effect of vitamin C on glycosylation
of proteins. Diabetes 1992;41:167–73.
146. Will JC, Tyers T. Does diabetes mellitus increase the requirement
for vitamin C? Nutr Rev 1996;54:193–202 [review].
147. Eriksson J, Kohvakka A. Magnesium and ascorbic acid supplementation
in diabetes mellitus. Ann Nutr Metab 1995;39:217–23.
148. Paolisso G, Balbi V, Volpe C, et al. Metabolic benefits deriving
from chronic vitamin C supplementation in aged non-insulin dependent diabetics. J Am Coll
Nutr 1995;14:387–92.
149. Will JC, Tyers T. Does diabetes mellitus increase the requirement
for vitamin C? Nutr Rev 1996;54:193–202 [review].
150. McAuliffe AV, Brooks BA, Fisher EJ, et al. Administration of
ascorbic acid and an aldose reductase inhibitor (tolrestat) in diabetes: effect on urinary
albumin excretion. Nephron 1998;80:277–84.
151. Branch DR. High-dose vitamin C supplementation increases plasma
glucose. Diabetes Care 1999;22:1218 [letter].
152. Mayer-Davis E, Bell RA, Reboussin BA, et al. Antioxidant nutrient
intake and diabetic retinopathy. The San Luis Valley Diabetes Study. Ophthalmology
1998;105:2264–70.
153. Wilson RG, Davis RE. Serum pyridoxal concentrations in children with
diabetes mellitus. Pathology 1977;9:95–9.
154. Davis RE, Calder JS, Curnow DH. Serum pyridoxal and folate
concentrations in diabetics. Pathology 1976;8:151–6.
155. McCann VJ, Davis RE. Serum pyridoxal concentrations in patients with
diabetic neuropathy. Aust N Z J Med 1978;8:259–61.
156. Spellacy WN, Buhi WC, Birk SA. Vitamin B6 treatment of gestational
diabetes mellitus. Am J Obstet Gynecol 1977;127:599–602.
157. Coelingh HJT, Schreurs WHP. Improvement of oral glucose tolerance in
gestational diabetes by pyridoxine. BMJ 1975;3:13–5.
158. Spellacy WN, Buhi WC, Birk SA. The effects of vitamin B6 on
carbohydrate metabolism in women taking steroid contraceptives: preliminary report.
Contraception 1972;6:265–73.
159. Passariello N, Fici F, Giugliano D, et al. Effects of pyridoxine
alpha-ketoglutarate on blood glucose and lactate in type I and II diabetics. Int J Clin
Pharmacol Ther Toxicol 1983;21:252–6.
160. Solomon LR, Cohen K. Erythrocyte O2 transport and metabolism and
effects of vitamin B6 therapy in type II diabetes mellitus. Diabetes
1989;38:881–6.
161. Rao RH, Vigg BL, Rao KSJ. Failure of pyridoxine to improve glucose
tolerance in diabetics. J Clin Endocrinol Metab 1980;50:198–200.
162. Abbas ZG, Swai ABM. Evaluation of the efficacy of thiamine and
pyridoxine in the treatment of symptomatic diabetic peripheral neuropathy. East African
Med J 1997;74:804–8.
163. Stracke H, Lindemann A, Federlin K. A benfotiamine-vitamin B
combination in treatment of diabetic polyneuropathy. Exp Clin Endocrinol Diabetes
1996;104:311–6.
164. Coggeshall JC, Heggers JP, Robson MC, Baker H. Biotin status and
plasma glucose in diabetics. Ann NY Acad Sci 1985;447:389–92.
165. Koutsikos D, Agroyannis B, Tzanatos-Exarchou H. Biotin for diabetic
peripheral neuropathy. Biomed Pharmacother 1990;44:511–4.
166. Yamane K, Usui T, Yamamoto T, et al. Clinical efficacy of
intravenous plus oral mecobalamin in patients with peripheral neuropathy using vibration
perception thresholds as an indicator of improvement. Curr Ther Res
1995;56:656–70 [review].
167. Kuwabara S, Nakazawa R, Azuma N, et al. Intravenous methylcobalamin
treatment for uremic and diabetic neuropathy in chronic hemodialysis patients. Intern
Med 1999;38:472–5.
168. Molnar GD, Berge KG, Rosevear JW, et al. The effect of nicotinic
acid in diabetes mellitus. Metabolism 1964;13:181–9.
169. Gaut ZN, Pocelinko R, Solomon HM, Thomas GB. Oral glucose tolerance,
plasma insulin, and uric acid excretion in man during chronic administration in nicotinic
acid. Metabolism 1971;20:1031–5.
170. Clearly JP. The importance of oxidant injury as a cause of impaired
mitochondrial oxidation in diabetes. J Orthomolec Med 1988;3:164–74.
171. Miyake Y, Shouzu A, Nishikawa M, et al. Effect of treatment of
3-hydroxy-3-methylglutaryl coenzyme I reductase inhibitors on serum coenzyme Q10 in diabetic
patients. Arzneimittelforschung 1999;49:324–9.
172. Shigeta Y, Izumi K, Abe H. Effect of coenzyme Q7 treatment on blood
sugar and ketone bodies of diabetics. J Vitaminol (Kyoto) 1966;12:293–8.
173. Abdel-Aziz MT, Abdou MS, Soliman K, et al. Effect of carnitine on
blood lipid pattern in diabetic patients. Nutr Rep Int 1984;29:1071–9.
174. Sima AA, Calvani M, Mehra M, Amato A. Acetyl-L-carnitine improves
pain, nerve regeneration, and vibratory perception in patients with chronic diabetic
neuropathy: an analysis of two randomized placebo-controlled trials. Diabetes Care
2005;28:89–94.
175. Nakamura T, Higashi A, Nishiyama S, et al. Kinetics of zinc status
in children with IDDM. Diabetes Care 1991;14:553–7.
176. Niewoehner CB, Allen JI, Boosalis M, et al. Role of zinc
supplementation in type II diabetes mellitus. Am J Med 1986;81:63–8.
177. Crary EJ, McCarty MF. Potential clinical applications for high-dose
nutritional antioxidants. Med Hypotheses 1984;13:77–98.
178. Labriji-Mestaghanmi H, Billaudel B, Garnier PE, Sutter BCJ. Vitamin
D and pancreatic islet function. I. Time course for changes in insulin secretion and content
during vitamin deprivation and repletion. J Endocrine Invest
1988;11:577–84.
179. Boucher BJ. Inadequate vitamin D status: does it contribute to the
disorders comprising syndrome ‘X’? Br J Nutr 1998;79:315–27
[review].
180. Borissova AM, Tankova T, Kirilov G, et al. The effect of vitamin D3
on insulin secretion and peripheral insulin sensitivity in type 2 diabetic patients. Int J
Clin Pract 2003;57:258–61.
181. Salway JG, Whitehead L, Finnegan JA, et al. Effect of
myo-inositol on peripheral-nerve function in diabetes. Lancet
1978;2:1282–4.
182. Franconi F, Di Leo MA, Bennardini F, Ghirlanda G. Is taurine
beneficial in reducing risk factors for diabetes mellitus? Neurochem Res
2004;29:143–50 [review].
183. Brons C, Spohr C, Storgaard H, et al. Effect of taurine treatment on
insulin secretion and action, and on serum lipid levels in overweight men with a genetic
predisposition for type II diabetes mellitus. Eur J Clin Nutr 2004;58:1239-47.
184. Nakamura T, Ushiyama C, Suzuki S, et al. Effects of taurine and
vitamin E on microalbuminuria, plasma metalloproteinase-9, and serum type IV collagen
concentrations in patients with diabetic nephropathy. Nephron
1999;83:361–2.
185. Zak A, Zeman M, Hrabak P, et al. Changes in the glucose tolerance
and insulin secretion in hypertriglyceridemia: effects of dietary n-3 fatty acids. Nutr
Rep Int 1989;39:235–42.
186. Popp-Snijders C, Schouten JA, Heine RJ, et al. Dietary
supplementation of omega-3 polyunsaturated fatty acids improves insulin sensitivity in
non-insulin-dependent diabetes. Diabetes Res 1987;4:141–7.
187. Albrink MJ, Ullrich IH, Blehschmidt NG, et al. The beneficial effect
of fish oil supplements on serum lipids and clotting function of patients with type II
diabetes mellitus. Diabetes 1986;35 (suppl 1):43A [abstract #172].
188. Wei I, Ulchaker M, Sheehan J. Effect of omega-3 fatty acids (FA) in
non-obese non-insulin dependent diabetes (NIDDM). Am Clin Nutr 1988;47:775 [abstract
#70].
189. Okuda Y, Mizutani M, Ogawa M, et al. Long-term effects of
eicosapentaenoic acid on diabetic peripheral neuropathy and serum lipids in patients with type
II diabetes mellitus. J Diabetes Complications 1996;10:280–7.
190. Vandongen R, Mori TA, Codde JP, et al. Hypercholesterolaemic effect
of fish oil in insulin-dependent diabetic patients. Med J Aust
1988;148:141–3.
191. Schectman G, Kaul S, Kissebah AH. Effect of fish oil concentrate on
lipoprotein composition in NIDDM. Diabetes 1988;37:1567–73.
192. Stackpoole PW, Alig J, Kilgore LL, et al. Lipodystrophic diabetes
mellitus. Investigations of lipoprotein metabolism and the effects of omega-3 fatty acid
administration in two patients. Metabolism 1988;37:944–51.
193. Glauber H, Wallace P, Griver K, Brechtel G. Adverse metabolic effect
of omega-3 fatty acids in non-insulin-dependent diabetes mellitus. Ann Intern Med
1988;108:663–8.
194. Gaby A. Preventing complications of diabetes Townsend
Letter 1985;32:307 [editorial].
195. Halberstam M, Cohen N, Schlimovich P, et al. Oral vanadyl sulfate
improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. Diabetes
1996;45:659–66.
196. Boden G, Chen X, Ruiz J, et al. Effects of vanadyl sulfate on
carbohydrate and lipid metabolism in patients with non-insulin dependent diabetes mellitus.
Metabolism 1996;45:1130–5.
197. Goldfine AB, Patti ME, Zuberi L, et al. Metabolic effects of vanadyl
sulfate in humans with non-insulin-dependent diabetes mellitus: in vivo and in vitro studies.
Metabolism 2000;49:400–10.
198. Goldfine AB, Patti ME, Zuberi L, et al. Metabolic effects of vanadyl
sulfate in humans with non-insulin-dependent diabetes mellitus: In vivo and in vitro studies.
Metabolism 2000;49:400–10.
199. Yamashita K, Kawai K, Itakura M. Effect of fructo-oligosaccharides
on blood glucose and serum lipids in diabetic subjects. Nutr Res
1984;4:961–6.
200. Roberfroid M. Dietary fibre, inulin and oligofructose. A review
comparing their physiological effects. Crit Rev Food Sci Nutr 1993;33:103–48
[review].
201. van Dokkum W, Wezendonk B, Srikumar TS, van den Heuvel. Effect of
nondigestible oligosaccharides on large-bowel functions, blood lipid concentrations and
glucose absorption in young healthy male subjects. Eur J Clin Nutr
1999;53:1–7.
202. Luo J, Rizkalla SW, Alamowitch C, et al. Chronic consumption of
short-chain fructooligosaccharides by health subjects decreased basal hepatic glucose
production but had no effect on insulin-stimulated glucose metabolism. Am J Clin Nutr
1996;63:939–45.
203. Kosenko LG. Concentration of trace elements in the blood of patients
with diabetes mellitus. Fed Proc Transl (Suppl) 1965;24:237–8.
204. Baly DL, Schneiderman JS, Garcia-Welsh AL. Effect of manganese
deficiency on insulin binding, glucose transport and metabolism in rat adipocytes. J
Nutr 1990;120:1075–9.
205. Rubenstein AH, Levin NW, Elliott GA. Hypoglycaemia induced by
manganese. Nature (London) 1962;194:188–9.
206. Eckel RH, Hanson AS, Chen AY, et al. Dietary substitution of
medium-chain triglycerides improves insulin-mediated glucose metabolism in non-insulin
dependent diabetics. Diabetes 1992;41:641–7.
207. Trudy J, Yost RN, Erskine JM, et al. Dietary substitution of
medium-chain triglycerides in subjects with non-insulin dependent diabetes mellitus in an
ambulatory setting: impact on glycemic control and insulin-mediated glucose metabolism. J
Am Coll Nutr 1994;13:615–22.
208. Boivin M, Zinsmeister AR, Go VL, DiMagno EP. Effect of a purified
amylase inhibitor on carbohydrate metabolism after a mixed meal in healthy humans. Mayo
Clin Proc 1987;62:249–55.
209. Boivin M, Flourie B, Rizza RA, et al. Gastrointestinal and metabolic
effects of amylase inhibition in diabetics. Gastroenterology
1988;94:387–94.
210. Lankisch M, Layer P, Rizza RA, DiMagno EP. Acute postprandial
gastrointestinal and metabolic effects of wheat amylase inhibitor (WAI) in normal, obese, and
diabetic humans. Pancreas 1998;17:176–81.
211. Holt PR, Thea D, Yang MY, Kotler DP. Intestinal and metabolic
responses to an alpha-glucosidase inhibitor in normal volunteers. Metabolism
1988;37:1163–70.
212. Layer P, Rizza RA, Zinsmeister AR, et al. Effect of a purified
amylase inhibitor on carbohydrate tolerance in normal subjects and patients with diabetes
mellitus. Mayo Clin Proc 1986;61:442–7.
213. Rajasekaran S, Sivagnanam K, Subramanian S. Hypoglycemic effect of
Aloe vera gel on streptozotocin-induced diabetes in experimental rats. J Med Food
2004;7:61–6.
214. Yongchaiyudha S, Rungpitarangs V, Bunyapraphatsara N,
Chokechaijaroenporn O. Antidiabetic activity of Aloe vera L. juice. I. Clinical trial
in new cases of diabetes mellitus. Phytomedicine 1996;3:241–3.
215. Bunyapraphatsara N, Yongchaiyudha S, Rungpitarangsi V,
Chokechaijaroenporn O. Antidiabetic activity of Aloe vera L juice. II. Clinical trial
in diabetes mellitus patients in combination with glibenclamide. Phytomedicine
1996;3:245–8.
216. Vogler BK, Ernst E. Aloe vera: a systematic review of its clinical
effectiveness. Br J Gen Pract 1999;49:823–8 [review].
217. [No authors listed.] Treatment of painful diabetic neuropathy with
topical capsaicin. A multicenter, double-blind, vehicle-controlled study. The Capsaicin Study
Group. Arch Intern Med 1991;151:2225–9.
218. [No authors listed.] Effect of treatment with capsaicin on daily
activities of patients with painful diabetic neuropathy. Capsaicin Study Group. Diabetes
Care 1992;15:159–65.
219. Hannan JM, Rokeya B, Faruque O, et al. Effect of soluble dietary
fibre fraction of Trigonella foenum graecum on glycemic, insulinemic, lipidemic and platelet
aggregation status of Type 2 diabetic model rats. J Ethnopharmacol
2003;88:73–7.
220. Broca C, Manteghetti M, Gross R, et al. 4-Hydroxyisoleucine: effects
of synthetic and natural analogues on insulin secretion. Eur J Pharmacol
2000;390:339